A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated with Glycoprotein IIb/IIIa Receptor Inhibitors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-02

AUTHORS

Joan Llevadot, Stephanie A. Coulter, Robert P. Giugliano

ABSTRACT

The introduction of drugs that inhibit the GP IIb/IIIa receptor represents one of the most important new developments in the field of cardiovascular pharmacotherapeutics of the past decade. Thrombocytopenia associated with a GP IIb/IIIa inhibitor can occur in up to 5% of patients and is associated with poor clinical outcomes. Monitoring of the platelet count early after administration of these drugs is recommended and further assessment of the platelet count should be performed with long-term oral administration. Confirmation of true thrombocytopenia and an investigation of other potential etiologies are crucial initial diagnostic steps that should be taken when a platelet count of <100, 000/cm(3) is encountered. In patients receiving concomitant heparin, identification of heparin-induced thrombocytopenia using an enzyme-linked immunosorbent assay to detect anti-heparin-PF4 antibodies is preferred. Treatment recommendations depend upon the severity of thrombocytopenia and presence of bleeding. In general, GP IIb/IIIa inhibitor therapy should be stopped; conventional critical care instituted; and platelet transfusions considered if the platelet count is <10,000/cm(3), if there is severe bleeding, or if an emergency invasive procedure is required. Readministration of GP IIb/IIIa inhibitors may be associated with an increased risk of thrombocytopenia in selected circumstances, and caution is advised if the patient had previously experienced a significant decline in the platelet count or developed drug-induced antibodies following prior use. Future areas of research should target the mechanism(s) of thrombocytopenia, more accurate diagnostic methods, and the risk of thrombocytopenia when these drugs are combined with other antiplatelet and anticoagulant agents. More... »

PAGES

175-180

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1018779116791

DOI

http://dx.doi.org/10.1023/a:1018779116791

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007231143

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10613999


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Management", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Glycoprotein GPIIb-IIIa Complex", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Predictive Value of Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombocytopenia", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Cardiovascular Division, Brigham & Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Llevadot", 
        "givenName": "Joan", 
        "id": "sg:person.01224726434.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224726434.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cardiovascular Division, Brigham & Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coulter", 
        "givenName": "Stephanie A.", 
        "id": "sg:person.01172611122.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172611122.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cardiovascular Division, Brigham & Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giugliano", 
        "givenName": "Robert P.", 
        "id": "sg:person.0702207604.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702207604.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0735-1097(98)00134-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001747158"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199505183322003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006959942"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.99.22.2892", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012501908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(98)00252-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014505465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0735-1097(94)90634-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025598401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1008887708104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028310016", 
          "https://doi.org/10.1023/a:1008887708104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.2830500105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036821216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-8703(98)70243-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045183197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)11086-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052877313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(97)84511-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054658752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.95.4.809", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063337837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-115-4-256", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073695908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-127-9-199711010-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073701794"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-127-9-199711010-00012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073701801"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074488288", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077879541", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0038-1649626", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082391888"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0038-1651670", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082488065"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-02", 
    "datePublishedReg": "2000-02-01", 
    "description": "The introduction of drugs that inhibit the GP IIb/IIIa receptor represents one of the most important new developments in the field of cardiovascular pharmacotherapeutics of the past decade. Thrombocytopenia associated with a GP IIb/IIIa inhibitor can occur in up to 5% of patients and is associated with poor clinical outcomes. Monitoring of the platelet count early after administration of these drugs is recommended and further assessment of the platelet count should be performed with long-term oral administration. Confirmation of true thrombocytopenia and an investigation of other potential etiologies are crucial initial diagnostic steps that should be taken when a platelet count of <100, 000/cm(3) is encountered. In patients receiving concomitant heparin, identification of heparin-induced thrombocytopenia using an enzyme-linked immunosorbent assay to detect anti-heparin-PF4 antibodies is preferred. Treatment recommendations depend upon the severity of thrombocytopenia and presence of bleeding. In general, GP IIb/IIIa inhibitor therapy should be stopped; conventional critical care instituted; and platelet transfusions considered if the platelet count is <10,000/cm(3), if there is severe bleeding, or if an emergency invasive procedure is required. Readministration of GP IIb/IIIa inhibitors may be associated with an increased risk of thrombocytopenia in selected circumstances, and caution is advised if the patient had previously experienced a significant decline in the platelet count or developed drug-induced antibodies following prior use. Future areas of research should target the mechanism(s) of thrombocytopenia, more accurate diagnostic methods, and the risk of thrombocytopenia when these drugs are combined with other antiplatelet and anticoagulant agents.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1018779116791", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1113719", 
        "issn": [
          "0929-5305", 
          "1573-742X"
        ], 
        "name": "Journal of Thrombosis and Thrombolysis", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated with Glycoprotein IIb/IIIa Receptor Inhibitors", 
    "pagination": "175-180", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "227198e9ad5ffabeb52f9b7a26df8c2608f6b81900c70ee717c586332c5261b4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10613999"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9502018"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1018779116791"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007231143"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1018779116791", 
      "https://app.dimensions.ai/details/publication/pub.1007231143"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000503.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023%2FA%3A1018779116791"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1018779116791'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1018779116791'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1018779116791'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1018779116791'


 

This table displays all metadata directly associated to this object as RDF triples.

167 TRIPLES      21 PREDICATES      54 URIs      28 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1018779116791 schema:about N090219aa6f38406ca807cd0059937a8e
2 N4c3282d40c834778a7dc2d5bf8779a6c
3 N5d7dd16ba8c14e4bb0bb092a8e5b323c
4 N6b26db4138f347d0bdebc901b8bf2082
5 N83f84ef230b14229a7d7d48d7f444f27
6 N898b662a448c4d79b120a958579bc4cf
7 Nf4a4a217cd8349d9ace3cac1c281a943
8 anzsrc-for:11
9 anzsrc-for:1102
10 schema:author Neb85633020844d879814018ff11ad7cb
11 schema:citation sg:pub.10.1023/a:1008887708104
12 https://app.dimensions.ai/details/publication/pub.1074488288
13 https://app.dimensions.ai/details/publication/pub.1077879541
14 https://doi.org/10.1002/ajh.2830500105
15 https://doi.org/10.1016/0735-1097(94)90634-3
16 https://doi.org/10.1016/s0002-8703(98)70243-1
17 https://doi.org/10.1016/s0140-6736(98)11086-3
18 https://doi.org/10.1016/s0735-1097(97)84511-1
19 https://doi.org/10.1016/s0735-1097(98)00134-x
20 https://doi.org/10.1016/s0735-1097(98)00252-6
21 https://doi.org/10.1055/s-0038-1649626
22 https://doi.org/10.1055/s-0038-1651670
23 https://doi.org/10.1056/nejm199505183322003
24 https://doi.org/10.1161/01.cir.95.4.809
25 https://doi.org/10.1161/01.cir.99.22.2892
26 https://doi.org/10.7326/0003-4819-115-4-256
27 https://doi.org/10.7326/0003-4819-127-9-199711010-00005
28 https://doi.org/10.7326/0003-4819-127-9-199711010-00012
29 schema:datePublished 2000-02
30 schema:datePublishedReg 2000-02-01
31 schema:description The introduction of drugs that inhibit the GP IIb/IIIa receptor represents one of the most important new developments in the field of cardiovascular pharmacotherapeutics of the past decade. Thrombocytopenia associated with a GP IIb/IIIa inhibitor can occur in up to 5% of patients and is associated with poor clinical outcomes. Monitoring of the platelet count early after administration of these drugs is recommended and further assessment of the platelet count should be performed with long-term oral administration. Confirmation of true thrombocytopenia and an investigation of other potential etiologies are crucial initial diagnostic steps that should be taken when a platelet count of <100, 000/cm(3) is encountered. In patients receiving concomitant heparin, identification of heparin-induced thrombocytopenia using an enzyme-linked immunosorbent assay to detect anti-heparin-PF4 antibodies is preferred. Treatment recommendations depend upon the severity of thrombocytopenia and presence of bleeding. In general, GP IIb/IIIa inhibitor therapy should be stopped; conventional critical care instituted; and platelet transfusions considered if the platelet count is <10,000/cm(3), if there is severe bleeding, or if an emergency invasive procedure is required. Readministration of GP IIb/IIIa inhibitors may be associated with an increased risk of thrombocytopenia in selected circumstances, and caution is advised if the patient had previously experienced a significant decline in the platelet count or developed drug-induced antibodies following prior use. Future areas of research should target the mechanism(s) of thrombocytopenia, more accurate diagnostic methods, and the risk of thrombocytopenia when these drugs are combined with other antiplatelet and anticoagulant agents.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N7e3ad72293444c2c929d6af1d05eb57c
36 Nc1aac4397d6f45e4b329198689203f26
37 sg:journal.1113719
38 schema:name A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated with Glycoprotein IIb/IIIa Receptor Inhibitors
39 schema:pagination 175-180
40 schema:productId N20915dba2da146dabbd36bde1f52982d
41 N43b5f26ef2e9442ab9c885d6bb80da2c
42 N6c394dbe02704587bfa93887a322230d
43 N74c589bdbada4675ba3af2b8a92934fe
44 N8c1fb18134cd43d9a235d323f1bc13c2
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007231143
46 https://doi.org/10.1023/a:1018779116791
47 schema:sdDatePublished 2019-04-11T00:14
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N446e1c8f975045248da43fcf74eeb880
50 schema:url http://link.springer.com/10.1023%2FA%3A1018779116791
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N090219aa6f38406ca807cd0059937a8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
55 schema:name Platelet Glycoprotein GPIIb-IIIa Complex
56 rdf:type schema:DefinedTerm
57 N1e945889ba8a47feadc066aabb76b53c schema:name Cardiovascular Division, Brigham & Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
58 rdf:type schema:Organization
59 N20915dba2da146dabbd36bde1f52982d schema:name nlm_unique_id
60 schema:value 9502018
61 rdf:type schema:PropertyValue
62 N43b5f26ef2e9442ab9c885d6bb80da2c schema:name readcube_id
63 schema:value 227198e9ad5ffabeb52f9b7a26df8c2608f6b81900c70ee717c586332c5261b4
64 rdf:type schema:PropertyValue
65 N446e1c8f975045248da43fcf74eeb880 schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N45d4c55c16454f4ea9204955a328c54b schema:name Cardiovascular Division, Brigham & Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
68 rdf:type schema:Organization
69 N4c3282d40c834778a7dc2d5bf8779a6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Predictive Value of Tests
71 rdf:type schema:DefinedTerm
72 N5d7dd16ba8c14e4bb0bb092a8e5b323c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Disease Management
74 rdf:type schema:DefinedTerm
75 N6b26db4138f347d0bdebc901b8bf2082 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Humans
77 rdf:type schema:DefinedTerm
78 N6c394dbe02704587bfa93887a322230d schema:name doi
79 schema:value 10.1023/a:1018779116791
80 rdf:type schema:PropertyValue
81 N6e9912476d29408bbead631f85d28df3 rdf:first sg:person.0702207604.00
82 rdf:rest rdf:nil
83 N74c589bdbada4675ba3af2b8a92934fe schema:name dimensions_id
84 schema:value pub.1007231143
85 rdf:type schema:PropertyValue
86 N7e3ad72293444c2c929d6af1d05eb57c schema:issueNumber 2
87 rdf:type schema:PublicationIssue
88 N83f84ef230b14229a7d7d48d7f444f27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Thrombocytopenia
90 rdf:type schema:DefinedTerm
91 N898b662a448c4d79b120a958579bc4cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Platelet Count
93 rdf:type schema:DefinedTerm
94 N8c1fb18134cd43d9a235d323f1bc13c2 schema:name pubmed_id
95 schema:value 10613999
96 rdf:type schema:PropertyValue
97 N8ca44462980f4690958a8a4b4d6f0a74 schema:name Cardiovascular Division, Brigham & Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
98 rdf:type schema:Organization
99 Nb4514b850a9c40c3b20bd0ea56f81fdc rdf:first sg:person.01172611122.31
100 rdf:rest N6e9912476d29408bbead631f85d28df3
101 Nc1aac4397d6f45e4b329198689203f26 schema:volumeNumber 9
102 rdf:type schema:PublicationVolume
103 Neb85633020844d879814018ff11ad7cb rdf:first sg:person.01224726434.25
104 rdf:rest Nb4514b850a9c40c3b20bd0ea56f81fdc
105 Nf4a4a217cd8349d9ace3cac1c281a943 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Platelet Aggregation Inhibitors
107 rdf:type schema:DefinedTerm
108 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
109 schema:name Medical and Health Sciences
110 rdf:type schema:DefinedTerm
111 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
112 schema:name Cardiorespiratory Medicine and Haematology
113 rdf:type schema:DefinedTerm
114 sg:journal.1113719 schema:issn 0929-5305
115 1573-742X
116 schema:name Journal of Thrombosis and Thrombolysis
117 rdf:type schema:Periodical
118 sg:person.01172611122.31 schema:affiliation N1e945889ba8a47feadc066aabb76b53c
119 schema:familyName Coulter
120 schema:givenName Stephanie A.
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172611122.31
122 rdf:type schema:Person
123 sg:person.01224726434.25 schema:affiliation N8ca44462980f4690958a8a4b4d6f0a74
124 schema:familyName Llevadot
125 schema:givenName Joan
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224726434.25
127 rdf:type schema:Person
128 sg:person.0702207604.00 schema:affiliation N45d4c55c16454f4ea9204955a328c54b
129 schema:familyName Giugliano
130 schema:givenName Robert P.
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702207604.00
132 rdf:type schema:Person
133 sg:pub.10.1023/a:1008887708104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028310016
134 https://doi.org/10.1023/a:1008887708104
135 rdf:type schema:CreativeWork
136 https://app.dimensions.ai/details/publication/pub.1074488288 schema:CreativeWork
137 https://app.dimensions.ai/details/publication/pub.1077879541 schema:CreativeWork
138 https://doi.org/10.1002/ajh.2830500105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036821216
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1016/0735-1097(94)90634-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025598401
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1016/s0002-8703(98)70243-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045183197
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1016/s0140-6736(98)11086-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052877313
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1016/s0735-1097(97)84511-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054658752
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1016/s0735-1097(98)00134-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001747158
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/s0735-1097(98)00252-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014505465
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1055/s-0038-1649626 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082391888
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1055/s-0038-1651670 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082488065
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1056/nejm199505183322003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006959942
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1161/01.cir.95.4.809 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063337837
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1161/01.cir.99.22.2892 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012501908
161 rdf:type schema:CreativeWork
162 https://doi.org/10.7326/0003-4819-115-4-256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073695908
163 rdf:type schema:CreativeWork
164 https://doi.org/10.7326/0003-4819-127-9-199711010-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073701794
165 rdf:type schema:CreativeWork
166 https://doi.org/10.7326/0003-4819-127-9-199711010-00012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073701801
167 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...